BioAge Labs, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge Labs serves customers worldwide.

Current Report (Form 8-K | Period ending 2025-12-04)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BioAge Labs (BIOA US)

Current Report (Form 8-K | Period ending 2025-12-04)

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

S-3/A | Registration statement for specified transactions by certain issuers (Amendment)

S-3/A | Registration statement for specified transactions by certain issuers (Amendment)

S-3 | Registration statement for specified transactions by certain issuers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)